| Product Unit Size | Cost | Quantity | Stock |
|---|
Resiquimod is an imidazoquinoline compound that is a TLR7/8 agonist. Resiquimod has been shown to activate dendritic cells in both healthy and inflamed skin, making it effective to induce regression of cutaneous T-cell lymphoma lesions. BALB/c mice treated with resiquimod showed high levels of resistance against parasitic infection. Furthermore, resiquimod has been shown to produce cardioprotective effects in anoxia-regeneration injuries of neonatal cardiomyocytes.
| Cas No. | 144875-48-9 |
|---|---|
| Purity | ≥98% |
| Formula | C17H22N4O2 |
| Formula Wt. | 314.39 |
| Chemical Name | 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol |
| IUPAC Name | 1-[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methyl-2-propanol |
| Synonym | R-848, R848, S28463, alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol. |
| Solubility | Soluble in DMSO (100 mM), ethanol (50 mM), 100% or 5% methanol, and dichloromethane. Insoluble in water. |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Rook AH, Gelfand JM, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015 Sep 17;126(12):1452-1461. PMID: 26228486.
Craft N, Birnbaum R, Quanquin N, et al. Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice. Clin Vaccine Immunol. 2014 Sep;21(9):1314-1322. PMID: 25030052.
Wang YY, Liu S, Lian F, et al. Toll-like receptor 7/8 agonist resiquimod induces late preconditioning in neonatal cardiac myocytes. Acta Pharmacol Sin. 2011 May;32(5):565-572. PMID: 21516132.
